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Abstract
Background: There is no consensus on diagnosis and management of ASBO. Initial conservative management is
usually safe, however proper timing for discontinuing non operative treatment is still controversial. Open surgery or
laparoscopy are used without standardized indications.
Methods: A panel of 13 international experts with interest and background in ASBO and peritoneal diseases,
participated in a consensus conference during the 1
st International Congress of the World Society of Emergency
Surgery and 9
th Peritoneum and Surgery Society meeting, in Bologna, July 1-3, 2010, for developing evidence-
based recommendations for diagnosis and management of ASBO. Whenever was a lack of high-level evidence, the
working group formulated guidelines by obtaining consensus.
Recommendations: In absence of signs of strangulation and history of persistent vomiting or combined CT scan signs (free
fluid, mesenteric oedema, small bowel faeces sign, devascularized bowel) patients with partial ASBO can be managed safely
with NOM and tube decompression (either with long or NG) should be attempted. These patients are good candidates for
Water Soluble Contrast Medium (WSCM) with both diagnostic and therapeutic purposes. The appearance of water-soluble
contrast in the colon on X-ray within 24 hours from administration predicts resolution. WSCM may be administered either
orally or via NGT (50-150 ml) both immediately at admission or after an initial attempt of conservative treatment of 48 hours.
The use of WSCM for ASBO is safe and reduces need for surgery, time to resolution and hospital stay.
NOM, in absence of signs of strangulation or peritonitis, can be prolonged up to 72 hours. After 72 hours of NOM
without resolution surgery is recommended.
Patients treated non-operatively have shorter hospital stay, but higher recurrence rate and shorter time to re-
admission, although the risk of new surgically treated episodes of ASBO is unchanged. Risk factors for recurrences
are age <40 years and matted adhesions. WSCM does not affect recurrence rates or recurrences needing surgery
when compared to traditional conservative treatment.
Open surgery is the preferred method for surgical treatment of strangulating ASBO as well as after failed conservative
management. In selected patients and with appropriate skills, laparoscopic approach can be attempted using open access
technique. Access in the left upper quadrant should be safe. Laparoscopic adhesiolysis should be attempted preferably in
case of first episode of SBO and/or anticipated single band. A low threshold for open conversion should be maintained.
Peritoneal adhesions should be prevented. Hyaluronic acid-carboxycellulose membrane and icodextrin can reduce
incidence of adhesions. Icodextrin may reduce the risk of re-obstruction. HA cannot reduce need of surgery.
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Any intra-abdominal surgical procedure is a procedure
inside the peritoneal organ. Intra-abdominal adhesions
are strands or membranes of fibrous tissue that can be
attached to the various intraabdominal organs, gluing
them strongly together.
Abdominal adhesions, which can begin forming within
a few hours after an operation, represent the most com-
mon cause of intestinal obstruction being responsible
for 60% to 70% of SBO [1,2].
Complications of adhesions include chronic pelvic
pain (20-50% incidence), small bowel obstruction (49-
74% incidence), intestinal obstruction in ovarian cancer
patients (22% incidence), and infertility due to complica-
tions in the fallopian tube, ovary, and uterus (15-20%
incidence) [3,4]. Pelvic adhesions were found to be
responsible in 15% to 40% of infertilities [5,6].
Intraabdominal adhesions related to prior abdominal
surgery is the etiologic factor in up to 75% of cases of
small-bowel obstruction. More than 300,000 patients are
estimated to undergo surgery to treat adhesion-induced
small-bowel obstruction in the United States annually.
In details adhesiolysis was responsible for 303,836 hospi-
talizations during 1994, primarily for procedures on the
digestive and female reproductive systems and these
procedures accounted for 846,415 days of inpatient care
and $1.3 billion in hospitalization and surgeon expendi-
tures [7]. Foster et al. reported in 2005 that during the
year 1997 in the state of California, SBO accounted for
32,583 unscheduled admissions, and approximately 85%
were secondary to adhesions [8].
Abdominal adhesions pose a significant health problem
with major adverse effects on quality of life, use of health
care resources, and financial costs. Incidence rates for
abdominal adhesions have been estimated to be as high
as 94% [9] -95% [10] after laparotomies. The presence of
adhesions makes re-operation more difficult, adds an
average of 24 minutes to the surgery, increases the risk of
iatrogenic bowel injury, and makes future laparoscopic
surgery more difficult or even not possible [11,12].
Background of Bologna Guidelines
Adhesive small bowel obstruction require appropriate
management with a proper diagnostic and therapeutic
pathway. Indication and length of Non Operative treat-
ment and appropriate timing for surgery may represent
an insidious issue.
D e l a yi ns u r g i c a lt r e a t m e n tm a yc a u s eas u b s t a n t i a l
increase of morbidity and mortality. However repeated
laparotomy and adhesiolysis may worsen the process of
adhesion formation and their severity. Furthermore the
introduction and widespread of laparoscopy has raised
the question of selection of appropriate patients with
ASBO good candidate for laparoscopic approach. On
the other hand, several adjuncts for improving the suc-
cess rate of NOM and clarifying indications and timing
for surgery are currently available, such as hyperosmolar
water soluble contrast medium.
No consensus has been reached in diagnosing and
managing the patients with ASBO and specific and
updated guidelines are lacking.
We carried out an extensive review of the English-lan-
guage literature and found that there was little high-
level evidence in this field, and no systematically
described practical manual for the field. Most impor-
tantly, there are no standardized diagnostic criteria and
therapeutic management guidelines for ASBO, therefore,
we would like to establish standards for these items.
The Bologna Guidelines include evidence-based medi-
cine and reflect the international consensus obtained
through earnest discussions among professionals in the
field on 1-3 July, 2010, at the Belmeloro Convention
Center, Bologna, Italy.
Notes on the use of the Guidelines
The Guidelines are evidence-based, with the grade of
recommendation also based on the evidence. The
Guidelines present the diagnostic and therapeutic meth-
ods for optimal management and prevention of ASBO.
The practice Guidelines promulgated in this work do
not represent a standard of practice. They are suggested
plans of care, based on best available evidence and the
consensus of experts, but they do not exclude other
approaches as being within the standard of practice. For
example, they should not be used to compel adherence
to a given method of medical management, which
method should be finally determined after taking
account of the conditions at the relevant medical insti-
tution (staff levels, experience, equipment, etc.) and the
characteristics of the individual patient. However,
responsibility for the results of treatment rests with
those who are directly engaged therein, and not with
the consensus group.
Methods
- Consensus Development
In the Consensus Conference on July 2
nd 2010, the
expert panel had two meetings and a further plenary
session. The aim was to focus and clarify the diagnostic
and therapeutic issues of the complex management of
ASBO, leading to new clinical guidelines, updated and
including a wide range of recommendations, for diagno-
sis, non operative management, timing for surgery, type
of surgery and prevention strategies of peritoneal post-
operative adhesions causing small bowel obstruction.
Based on the review of the current literature, a panel of
worldwide experts were invited to participate in the
development of the new guidelines. All members of the
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of diagnosis, treatment (conservative and surgical) and
prevention of ASBO, one expert summarized the cur-
rent state of the art. From the evidence based presenta-
tions and the reported statements as well as from the
results of the relevant literature review, a preliminary
document with the resume of the Consensus Statements
and Recommendations was compiled. For every key
statement, the discussion within the expert panel with
the involvement of the audience, took place until a
100% consensus within the group and the audience was
achieved. Comments from the audience were collected
and partly included in the manuscript. In September
2010 the expert panel had further contacts for discuss-
ing and finalize the final version of the text of the guide-
lines recommendations. The final version of the
guidelines was approved by all experts in the panel as
well as the experts from the audience who played an
active role in the discussion during the Consensus Con-
ference. Each ‘’chapter’’ consists of a key statement with
a grade of recommendation (GoR) followed by a com-
mentary to explain the rationale and evidence behind
the statement.
- Literature Searches and Appraisal
We have used the Oxford hierarchy for grading clinical
studies according to levels of evidence. Literature
searches were aimed at finding randomized (i.e., level 1b
evidence) or nonrandomized controlled clinical trials (i.
e., level 2b evidence). Alternatively, low-level evidence
(mainly case series and case reports; i.e., level 4 evi-
dence) was reviewed. Studies containing severe metho-
dological flaws were downgraded. For each intervention,
we considered the validity and homogeneity of study
results, effect sizes, safety, and economic consequences.
Systematic literature searches were conducted on
Medline and the Cochrane Library until December
2010. There were no restrictions regarding the language
of publication. We also paid attention to studies that
were referenced in systematic reviews or previous guide-
lines [http://www.east.org/tpg/sbo.pdf] [13].
- Categories of Evidence and Grades of Recommendation
All studies have been evaluated for quality according to
STARD checklist for the reporting of studies of diagnos-
tic accuracy (http://www.stard-statement.org)(Table 1).
Categories of evidence and Grades of Recommendation
have been assessed and classified according to the
Oxford Centre for Evidence-based Medicine Levels of
Evidence (Version March 2009) (Table 2 and Table 3).
Results
- Definition, risk factors, natural history and diagnosis
Patients with ASBO treated nonsurgically have shorter
hospital stay, however they have an higher recurrence
rate, shorter time to re-admission, although the risk of
new surgically treated episodes of ASBO is the same.
(Level of Evidence 2b)
All patients being evaluated for small bowel obstruction
should have plain films (Level of Evidence 2b GoR C)
CT-scans should not be routinely performed in the
decision-making process except when clinical history,
physical examination, and plain film are not conclusive
for small bowel obstruction diagnosis (Level of Evidence
2b GoR B)
The association of CT scan signs of bowel ischemia
should lead a low threshold for surgical intervention
(Level of Evidence 2a GoR B)
MRI and US are of limited value for ASBO and should
be limited to patients with contraindications for CT
scan/iodine contrast (Level of Evidence 2c GoR C)
In patients undergoing initial non operative conserva-
tive management, a water-soluble contrast follow-
through should be performed in order to rule out com-
plete ASBO and predict the need for surgery (Level of
Evidence 1b GoR A)
Adhesional postoperative small bowel obstruction is
characterized by the presence of abdominal pain, vomit-
ing, distention, and obstipation, in conjunction of confir-
matory imaging.
SBO can be classified according to completeness: Par-
tial vs. Complete (or high grade vs. low grade), according
to etiology: Adhesional vs. Non-adhesional, according to
timing: Early vs. Late (>30 days after surgery).
The most important risk factor for adhesive SBO is
the type of surgery and extent of peritoneal damage.
Surgeries of the colon and rectum are associated with a
higher risk of adhesion-related problems [14]. Total
colectomy with ileal pouch-anal anastomosis is the pro-
cedure with the highest incidence for adhesion-related
problems with an overall incidence of SBO of 19.3%.
Other high-risk procedures include gynecologic sur-
geries (11.1%) and open colectomy (9.5%).
Other possible risk factors include age younger than
60 years, previous laparotomy within 5 years, peritonitis,
multiple laparotomies, emergency surgery, omental
resection, and penetrating abdominal trauma, especially
gunshot wounds [15-18].
The number of prior episodes is the strongest predic-
tor of recurrence; in fact ASBO recurred after 53% of
initial episodes and 85% or more of second, third, or
later episodes in the experience of Barkan et al. Recur-
rence occurred sooner and more frequently in patients
managed nonoperatively than in patients managed
operatively [19].
With growing numbers of previous episodes of SBO
requiring adhesiolysis, the risk for future re-admission
for SBO increases, thus nonsurgical management of the
initial episode has been advocated as a risk factor for
recurrence [20].
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adhesions, and surgical complications during the surgi-
cal management of the first episode as independent
risks for recurrence [21].
Williams et al. [22] in a retrospective review of 329
patients (487 admissions) demonstrated that operatively
treated patients had a lower frequency of recurrence
(26.8% vs 40.5% P < 0.009) and a longer time interval to
recurrence (411 vs 153 days P < 0.004); however, they
also had a longer hospital stay than that of patients trea-
ted nonoperatively (12.0 vs 4.9 days; P < 0.0001). There
was no significant difference in treatment type or in
Table 1 STARD checklist for the reporting of studies of diagnostic accuracy
Section and Topic Item
#
TITLE/ABSTRACT/
KEYWORDS
1 Identify the article as a study of diagnostic accuracy (recommended MeSH heading ‘sensitivity and specificity’)
INTRODUCTION 2 State the research questions or study aims, such as estimating diagnostic accuracy or comparing accuracy between
tests or across participant groups
METHODS
Participants 3 Describe the study population: The inclusion and exclusion criteria, setting and locations where the data were
collected
4 Describe participant recruitment: Was recruitment based on presenting symptoms, results from previous tests, or the
fact that the participants had received the index tests or the reference standard?
5 Describe participant sampling: Was the study population a consecutive series of participants defined by the selection
criteria in items 3 and 4? If not, specify how participants were further selected
Test methods 6 Describe data collection: Was data collection planned before the index test and reference standard were performed
(prospective study) or after (retrospective study)?
7 Describe the reference standard and its rationale
8 Describe technical specifications of material and methods involved including how and when measurements were
taken, and/or cite references for index tests and reference standard
9 Describe definition of and rationale for the units, cutoffs and/or categories of the results of the index tests and the
reference standard
10 Describe the number, training and expertise of the persons executing and reading the index tests and the reference standard
Statistical methods 11 Describe whether or not the readers of the index tests and reference standard were blind (masked) to the results of
the other test and describe any other clinical information available to the readers
12 Describe methods for calculating or comparing measures of diagnostic accuracy, and the statistical methods used to
quantify uncertainty (e.g. 95% confidence intervals)
RESULTS 13 Describe methods for calculating test reproducibility, if done
Participants
14 Report when study was done, including beginning and ending dates of recruitment
15 Report clinical and demographic characteristics of the study population (e.g. age, sex, spectrum of presenting
symptoms, comorbidity, current treatments, recruitment centers
Test results 16 Report the number of participants satisfying the criteria for inclusion that did or did not undergo the index tests
and/or the reference standard; describe why participants failed to receive either test (a flow diagram is strongly
recommended)
17 Report time interval from the index tests to the reference standard, and any treatment administered between
18 Report distribution of severity of disease (define criteria) in those with the target condition; other diagnoses in
participants without the target condition
19 Report a cross tabulation of the results of the index tests (including indeterminate and missing results) by the results of
the reference standard; for continuous results, the distribution of the test results by the results of the reference standard
Estimates 20 Report any adverse events from performing the index tests or the reference standard
21 Report estimates of diagnostic accuracy and measures of statistical uncertainty (e.g. 95% confidence intervals)
22 Report how indeterminate results, missing responses and outliers of the index tests were handled.
23 Report estimates of variability of diagnostic accuracy between subgroups of participants, readers or centers, if done.
DISCUSSION 24 Report estimates of test reproducibility, if done
25 Discuss the clinical applicability of the study findings
MeSH: Medical subject heading.
STARD: STAndards for the Reporting of Diagnostic accuracy studies.
This checklist is found at:http://www.consort-statement.org/index.aspx?o=2965 and http://www.consort-statement.org/index.aspx?o=2967.
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Centre for Evidence-Based Medicine) http://www.cebm.net/index.aspx?o=1025 Oxford Centre for Evidence-based
Medicine Levels of Evidence (March 2009) (for definitions of terms used see glossary at http://www.cebm.net/?o=1116)
Level Therapy/Prevention,
Aetiology/Harm
Prognosis Diagnosis Differential
diagnosis/symptom
prevalence study
Economic and decision
analyses
1a SR (with
homogeneity*) of
RCTs
SR (with homogeneity*) of
inception cohort studies;
CDR† validated in different
populations
SR (with homogeneity*) of
Level 1 diagnostic studies;
CDR† with 1b studies from
different clinical centres
SR (with
homogeneity*) of
prospective cohort
studies
SR (with homogeneity*) of
Level 1 economic studies
1b Individual RCT (with
narrow Confidence
Interval‡)
Individual inception cohort
study with > 80% follow-up;
CDR† validated in a single
population
Validating** cohort study
with good††† reference
standards; or CDR† tested
within one clinical centre
Prospective cohort
study with good
follow-up****
Analysis based on clinically
sensible costs or alternatives;
systematic review(s) of the
evidence; and including multi-
way sensitivity analyses
1c All or none§ All or none case-series Absolute SpPins and
SnNouts††
All or none case-series Absolute better-value or
worse-value analyses ††††
2a SR (with
homogeneity*) of
cohort studies
SR (with homogeneity*) of
either retrospective cohort
studies or untreated control
groups in RCTs
SR (with homogeneity*) of
Level >2 diagnostic studies
SR (with
homogeneity*) of 2b
and better studies
SR (with homogeneity*) of
Level >2 economic studies
2b Individual cohort study
(including low quality
RCT; e.g., <80% follow-
up)
Retrospective cohort study
or follow-up of untreated
control patients in an RCT;
Derivation of CDR† or
validated on split-sample§§§
only
Exploratory** cohort study
with good††† reference
standards; CDR† after
derivation, or validated only
on split-sample§§§ or
databases
Retrospective cohort
study, or poor follow-
up
Analysis based on clinically
sensible costs or alternatives;
limited review(s) of the
evidence, or single studies;
and including multi-way
sensitivity analyses
2c “Outcomes” Research;
Ecological studies
“Outcomes” Research Ecological studies Audit or outcomes research
3a SR (with
homogeneity*) of
case-control studies
SR (with homogeneity*) of
3b and better studies
SR (with
homogeneity*) of 3b
and better studies
SR (with homogeneity*) of 3b
and better studies
3b Individual Case-Control
Study
Non-consecutive study; or
without consistently applied
reference standards
Non-consecutive
cohort study, or very
limited population
Analysis based on limited
alternatives or costs, poor
quality estimates of data, but
including sensitivity analyses
incorporating clinically
sensible variations.
4 Case-series (and poor
quality cohort and
case-control studies§§)
Case-series (and poor quality
prognostic cohort studies***)
Case-control study, poor or
non-independent reference
standard
Case-series or
superseded reference
standards
Analysis with no sensitivity
analysis
5 Expert opinion
without explicit critical
appraisal, or based on
physiology, bench
research or “first
principles”
Expert opinion without
explicit critical appraisal, or
based on physiology, bench
research or “first principles”
Expert opinion without
explicit critical appraisal, or
based on physiology, bench
research or “first principles”
Expert opinion
without explicit critical
appraisal, or based on
physiology, bench
research or “first
principles”
Expert opinion without
explicit critical appraisal, or
based on economic theory or
“first principles”
Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. Updated by Jeremy Howick
March 2009.
Notes
Users can add a minus-sign “-” to denote the level of that fails to provide a conclusive answer because:
EITHER a single result with a wide Confidence Interval.
OR a Systematic Review with troublesome heterogeneity.
Such evidence is inconclusive, and therefore can only generate Grade D recommendations.
* By homogeneity we mean a systematic review that is free of worrisome variations (heterogeneity) in the directions and degrees of results between individual
studies. Not all systematic reviews with statistically significant heterogeneity need be worrisome, and not all worrisome heterogeneity need be statistically
significant. As noted above, studies displaying worrisome heterogeneity should be tagged with a “-” at the end of their designated level.
† Clinical Decision Rule. (These are algorithms or scoring systems that lead to a prognostic estimation or a diagnostic category.)
‡ See note above for advice on how to understand, rate and use trials or other studies with wide confidence intervals.
§ Met when all patients died before the Rx became available, but some now survive on it; or when some patients died before the Rx became available, but none
now die on it.
§§ By poor quality cohort study we mean one that failed to clearly define comparison groups and/or failed to measure exposures and outcomes in the same
(preferably blinded), objective way in both exposed and non-exposed individuals and/or failed to identify or appropriately control known confounders and/or
failed to carry out a sufficiently long and complete follow-up of patients. By poor quality case-control study we mean one that failed to clearly define comparison
groups and/or failed to measure exposures and outcomes in the same (preferably blinded), objective way in both cases and controls and/or failed to identify or
appropriately control known confounders.
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Page 5 of 24incidence or type of prior surgery among patients with
early and late small bowel obstruction. The authors
have also reported [23] early postoperative mortality of
3% and long-term mortality of 7% with the following
independent risk factors: age >75 years old, medical
complications, and a mixed mechanism of obstruction.
Prevalence of medical and surgical morbidity was 8%
and 6%, respectively. Independent risk factors for medi-
cal complications were ASA class >/= III and bands and
for the surgical complications the number of obstructive
structures >/= 10, a nonresected intestinal wall injury,
and intestinal necrosis.
In a further multicenter prospective study [24] includ-
ing 286 patients operated for ASBO and followed up for
41 months, cumulative incidence of overall recurrence
was 15.9%, and for surgically managed recurrence 5.8%.
The risk factors for the overall recurrences were age
<40 years (hazard ratio [HR], 2.97), adhesion or matted
adhesion (HR, 3.79) and, for the surgically managed:
adhesions or matted adhesions (HR, 3.64), and post-
operative surgical complications (HR, 5.63). In this study
the number of recurring patients (21%) in absence of
resection is very high. The beneficial effect of intestinal
resection might relate to the decrease of the traumatized
intestinal serosa area. In this way, it may be hypothe-
sized that adhesive postoperative SBO frequency is
linked to the extent of both the parietal peritoneal
trauma (incision and site) and the intestinal serosa.
Miller et al. [25] in a review of 410 patients accounting
for 675 admissions found that a history of colorectal
surgery and vertical incisions tended to predispose to
multiple matted adhesions rather than an obstructive
band. They conclude that the likelihood of reobstruction
increases and the time to reobstruction decreases with
increasing number of previous episodes of obstruction.
Patients with matted adhesions have a greater recur-
rence rate than those with band adhesions. These
authors failed to find reliable clinical indicators of
impending strangulation and the optimum length of a
non operative trial for patients with acute ASBO
remains controversial.
Fevang et al. described the long term prognosis of 500
patients operated for ASBO with a median follow-up of
10 years and a maximum follow-up time of 40 years
[26]. The cumulative recurrence rate for patients oper-
ated once for ASBO was 18% after 10 years and 29% at
30 years. For patients admitted several times for ASBO,
the relative risk of recurrent ASBO increased with
increasing number of prior ASBO episodes. The cumu-
lative recurrence rate reached 81% for patients with 4 or
more ASBO admissions. Other factors influencing the
recurrence rate were the method of treatment of the
last previous ASBO episode (conservative versus surgi-
cal) and the number of abdominal operations prior to
the initial ASBO operation. The authors concluded that
the risk of recurrence increased with increasing number
of ASBO episodes. Most recurrent ASBO episodes occur
within 5 years after the previous one, but a considerable
risk is still present 10 to 20 years after an ASBO epi-
sode. Surgical treatment decreased the risk of future
admissions for ASBO, but the risk of new surgically
treated ASBO episodes was the same regardless of the
§§§ Split-sample validation is achieved by collecting all the information in a single tranche, then artificially dividing this into “derivation” and “validation”
samples.
†† An “Absolute SpPin” is a diagnostic finding whose Specificity is so high that a Positive result rules-in the diagnosis. An “Absolute SnNout” is a diagnostic
finding whose Sensitivity is so high that a Negative result rules-out the diagnosis.
‡‡ Good, better, bad and worse refer to the comparisons between treatments in terms of their clinical risks and benefits.
††† Good reference standards are independent of the test, and applied blindly or objectively to applied to all patients. Poor reference standards are haphazardly
applied, but still independent of the test. Use of a non-independent reference standard (where the ‘test’ is included in the ‘reference’, or where the ‘testing’
affects the ‘reference’) implies a level 4 study.
†††† Better-value treatments are clearly as good but cheaper, or better at the same or reduced cost. Worse-value treatments are as good and more expensive, or
worse and the equally or more expensive.
** Validating studies test the quality of a specific diagnostic test, based on prior evidence. An exploratory study collects information and trawls the data (e.g.
using a regression analysis) to find which factors are ‘significant’.
*** By poor quality prognostic cohort study we mean one in which sampling was biased in favour of patients who already had the target outcome, or the
measurement of outcomes was accomplished in <80% of study patients, or outcomes were determined in an unblinded, non-objective way, or there was no
correction for confounding factors.
**** Good follow-up in a differential diagnosis study is >80%, with adequate time for alternative diagnoses to emerge (for example 1-6 months acute, 1 - 5 years
chronic)
Table 3 Grading system for ranking recommendations in
clinical guidelines
Grade of
recommendation
A Good evidence to support a recommendation for
use
B Moderate evidence to support a
recommendation for use
C Poor evidence to support a recommendation, or
the effect may not exceed the adverse effects
and/or inconvenience (toxicity, interaction
between drugs and cost)
D Moderate evidence to support a
recommendation against use
E Good evidence to support a recommendation
against use
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recurrent ASBO episode was associated with a signifi-
cantly decreased risk of having conservatively treated
ASBO episodes in the future, but the need for subse-
quent surgery for ASBO was similar regardless of the
method of treatment.
First step of diagnostic work up [27] for ASBO is
supine and erect plain abdominal X-ray. Radiologic stig-
mata of SBO are the presence/coincidence of multiple
air-fluid levels, dilatation/distension of small bowel
loops and the absence of gas in the colonic section.
Plain film has sensitivity and specificity ranging from
65% to 80% [28]. Ultrasound can be useful only in
expert hands; US is usually of limited value in bowel
obstruction and/or in patients with distended bowel
because the air, limiting ultrasound transmission, may
obscure the underlying findings. The scan should be
performed through flanks to avoid distended SB [29].
Usual US findings are: distention, peristalsis (differential
diagnosis of ileus vs. mechanical SBO), differences in
mucosal folds around transition point, free fluid (sign of
ischemia) [30].
CT scan is highly diagnostic in SBO and has a great
value in all patients with inconclusive plain films for com-
plete or high grade SBO [31]. However CT-scans should
not be routinely performed in the decision-making process
except when clinical history, physical examination, and
plain film are not conclusive for small bowel obstruction
diagnosis [32]. CT can confirm the presence of complete
obstruction and allow the diagnosis of the cause of SBO, it
can also exclude a non-adhesional pathology and assess
the occurrence of strangulation with a sensitivity and spe-
cificity higher than 90% and a NPV of nearly 100% [33].
IV contrast is necessary. Oral is not
Water-soluble contrast follow-through is valuable in
patients undergoing initial non operative conservative
management in order to rule out complete ASBO and
predict the need for surgery [34].
This investigation is safer than barium in cases of per-
foration and peritoneal spread and has possible thera-
peutic value in the case of adhesive small intestine
obstruction [35].
MRI use should be restricted to those patients having
CT or iodine contrast contraindications.
- Conservative treatment and timing for surgery
The management of small bowel obstruction caused by
adhesions is controversial because surgery can induce
new adhesions, whereas conservative treatment does not
remove the cause of the obstruction [36]. Conservative
treatment involves nasogastric intubation, intravenous
fluid administration, and clinical observation. Strangula-
tion of the bowel requires immediate surgery, but intest-
inal ischemia can be difficult to determine clinically.
Several issues are raised when managing patients with
ASBO.
The first question is whether to operate or not to operate
Patients without the signs of strangulation or peritonitis
or history of persistent vomiting or combination of CT
scan signs (free fluid, mesenteric oedema, lack of faeces
signa, devascularized bowel) and partial ASBO can safely
undergo non-operative management (LoE 1a GoR A)
In the absence of any signs of strangulation, patients
with an adhesive SBO can be managed safely with non-
operative treatment and tube decompression should be
attempted (Level of Evidence 1b GoR A)
Patients who had surgery within the six weeks before
the episode of small bowel obstruction, patients with
signs of strangulation or peritonitis (fever, tachycardia
and leucocytosis, metabolic acidosis and continuous
pain), patients with irreducible hernia and patients who
started to have signs of resolution at the time of admis-
sion are NOT candidate for conservative treatment +/-
WSCA administration (Level of Evidence 1a GoR A)
Foster et al. in a population based appraisal [37] found
that patients who underwent operations during index
admission had longer lengths of stay, lower mortality,
fewer SBO readmissions, and longer time to readmission
than patients treated nonsurgically.
In a retrospective analysis of 123 patients admitted for
ASBO and having an initial period of non-operative
treatment, complete resolution occurred within 48 h in
75 (88%) cases, the remaining 10 had resolved by 72 h
[38]. On the other hand only three (2.4%) patients, initi-
ally treated non-operatively, had small bowel strangula-
tion. All three were operated on within 24 h of
admission when changes in clinical findings suggested
small bowel strangulation may be present. There were
no deaths in the group having an initial period of non-
operative treatment. Therefore, upon the authors con-
clusion, in the absence of any signs of strangulation,
patients with an adhesive SBO can be managed safely
with non-operative treatment.
In a prospective, randomized trial conducted to com-
pare NGT and LT decompression with respect to the
success of nonoperative treatment and morbidity of sur-
gical intervention in 55 patients with acute ASBO, out
of 28 patients managed with NGT and 27 with LT,
twenty-one patients ultimately required operation [39].
At operation, 3 patients in the NGT group had ischemic
bowel that required resection. Postoperative complica-
tions occurred in 23% of patients treated with NGT ver-
sus 38% of patients treated with LT and no deaths were
observed. Therefore patients with ASBO can safely be
given a trial of tube decompression upon hospital
admission, given the absence of complications in
patients treated with either type of tube decompression
coupled with acceptable morbidity rate.
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laparotomies for adhesions, prolonged conservative
treatment, including parenteral nutritional support may
be prudent and often avoid a complex high-risk proce-
dure [40].
Fevang et al. found that among 146 patients with SBO
initially treated conservatively, 93 (64%) settled without
operation, 9 (6%) had strangulated bowel and 3 (2%)
died [41]. Whereas of the 91 patients with partial
obstruction but no sign of strangulation, 72 (79%)
resolved on conservative treatment. Therefore the
authors recommended that patients with partial obstruc-
tion and no sign of strangulation should initially be
treated conservatively. Furthermore when complete
obstruction is present, it may settle on conservative
management, but the use of supplementary diagnostic
tools might be desirable to find the patients who will
need early operative treatment.
In another review, out of 329 patients with SBO 43%
were successfully treated conservatively, whereas 57%
failed conservative treatment and underwent surgery
[42]. Overall, there were eight early deaths, four in each
group (2.8% conservative vs. 2.1% surgical; p = ns). Out
of these patients presenting with SBO, 63% had abdom-
inal surgery and 37% had no prior abdominal surgery
before developing a small bowel obstruction.
In conclusion, the most recent meta-analyses [43-45]
showed that the patients who had surgery within the six
weeks before the episode of small bowel obstruction,
patients with signs of strangulation or peritonitis (fever,
tachycardia and leucocytosis), patients with carcinoma-
tosis, patients with irreduc i b l eh e r n i aa n dp a t i e n t s
who started to have signs of resolution at the time of
admission are not candidate for conservative treatment
+/- Water Soluble Contrast Medium administration.
Also the EAST guidelines on SBO management
recommend that the patients with plain film finding of
small bowel obstruction and Clinical markers (fever,
leukocytosis, tachycardia, metabolic acidosis and contin-
uous pain) or peritonitis on physical exam warrant
exploration [46].
The second question is who can be safely managed with
initial conservative management and which factors can
reliably predict surgery
Complete SBO (no evidence of air within the large
bowel) and increased serum creatine phosphokinase pre-
dicts NOM failure (Level of Evidence 2b GoR C)
Free intraperitoneal fluid, mesenteric edema, lack of the
‘’small bowel feces sign’’ at CT, and history of vomiting,
severe abdominal pain (VAS > 4), abdominal guarding,
raised WCC and devascularized bowel at CT predict the
need for emergent laparotomy at the time of admission
(Level of Evidence 2c GoR C)
The appearance of water-soluble contrast in the colon
on abdominal X ray within 24 hours of its administra-
tion predicts resolution of ASBO (Level of Evidence 1a
GoR A)
Among patients with adhesive small bowel obstruction
(ASBO) initially managed with a conservative strategy,
predicting risk of operation is difficult.
Several recent studies have tried to focus on identify-
ing predictive factors for failure of NOM and need for
surgery.
In conservatively treated patients with ASBO, the drai-
nage volume through the long tube on day 3 (cut-off
value; 500mL) was the indicator for surgery [47].
In 2010 Komatsu et al. have developed a simple model
for predicting the need of surgery in patients who initially
undergo conservative management for ASBO. The model
included 3 variables: age >65 years, presence of ascites on
CT scan and drainage volume from NGT or LT > 500
mL on day 3. PPV of this model in the high-risk class
was 72% with specificity of 96%, whereas NPV in the low
risk class was 100% with sensitivity of 100% [48].
Tachycardia, fever, focal tenderness, increased white
blood cell counts, and elevated lactate levels can indicate
intestinal ischemia, but these indicators are not very spe-
cific [49]. When intestinal ischemia is unlikely, a conser-
vative approach can be followed for 24-48 h. Meagher et
al. have suggested that surgery is unavoidable in patients
with small bowel obstruction after previous appendect-
omy or surgery on the fallopian tubes or ovaries [50].
In another recently developed model for predicting the
risk of strangulated SBO, six variables correlated with
small bowel resection: history of pain lasting 4 days or
more, guarding, C-reactive protein level at least 75 mg/l,
leucocyte count 10 × 10(9)/l or greater, free intraperito-
neal fluid volume at least 500 ml on computed tomogra-
phy (CT) and reduction of CT small bowel wall contrast
enhancement [51].
A further multivariate predictive model of surgical
operation in SBO [52], showed free intraperitoneal fluid,
mesenteric edema, lack of the ‘’small bowel feces sign’’
at CT, and history of vomiting to be significant predic-
tors of the need for operative exploration.
In a retrospective study of 53 patients with ASBO trea-
ted using a long nasointestinal tube (LT), complete SBO
(no evidence of air within the large bowel) and increased
serum creatine phosphokinase (>or = 130 IU/L) were
independent predictive factors for LT decompression
failure [53].
A recent prospective study aimed to evaluate an algo-
rithm using CT-scans and Gastrografin in the manage-
ment of small bowel obstruction, severe abdominal pain
(VAS > 4), abdominal guarding, raised WCC and devas-
cularized bowel at CT predict the need for emergent
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this study demonstrated the diagnostic role of Gastro-
grafin in discriminating between partial and complete
small bowel obstruction whilst CT-scans were disap-
pointing in their ability to predict the necessity of emer-
gent laparotomies.
Again two systematic reviews confirmed the value of
water soluble contrast medium in predicting need for
surgery in ASBO patients.
Abbas et al. in 2007 already confirmed that Water-solu-
ble contrast followed by an abdominal radiograph after at
least 4 hours can accurately predict the likelihood of reso-
lution of a small bowel obstruction [55] and that appear-
ance of water-soluble contrast agent in the colon on an
abdominal radiograph within 24 h of its administration
predicted resolution of obstruction with a pooled sensitiv-
ity of 97 per cent and specificity of 96 per cent [56].
Branco et al. as well found that the appearance of WS
contrast in the colon within 4-24 h after administration
accurately predicts resolution of ASBO with a sensitivity
of 96 per cent and specificity of 98 per cent [57].
In conclusion patients without the above mentioned
clinical picture (including all signs of strangulation and/
orperitonitis etc.) and a partial SBO or a complete SBO
can both undergo non-operative management safely;
although, complete obstruction has a higher level of fail-
ure [58].
Third issue is which conservative management can be
adopted and which adjuncts can be used
There are no advantages with the use of long tube
decompression compared with the use of nasogastric
tubes. (Level of Evidence 1b GoR A)
However early tube decompression, either with long
or nasogastric tube, may be beneficial (Level of Evidence
2b GoR C)
The use of Gastrografin in ASBO is safe (in terms of
morbidity and mortality) and reduces the need for sur-
gery, the time to resolution of obstruction and the hos-
pital stay (Level of Evidence 1a GoR A)
Gastrografin may be administered on the dosage of
50-150 ml, either orally or via NGT and can be given
both at immediately admission or after an attempt of
initial traditional conservative treatment of 48 hours
(Level of Evidence 1b GoR A)
Oral therapy with magnesium oxide, L. acidophilus and
simethicone may hasten the resolution of conservatively
treated partial adhesive small bowel obstruction and
shorten the hospital stay (Level of Evidence 1b GoR A)
Hyperbaric oxygen (HBO) therapy may be beneficial
in non operative management of ASBO, especially in
older patients with high anesthesiologic risk (Level of
Evidence 2b GoR B)
A prospective RCT comparing tube decompression
with either Naso-Gastric Tube or Long intestinal tube,
failed to demonstrate any advantage of one type of tube
over the other in patients with adhesive SBO [out of 21
patients who ultimately required operation, 13 have
been managed with NGT (46%) and 8 with LT (30%)
(p= 0.16)] [59]. However at operation, 3 patients in the
NGT group had ischemic bowel that required resection
and, although not proven, the abscence of strangulation
in LT group may be attributed to the superior intralum-
inal decompression provided by LT as compared with
NGT. Postoperative complications occurred in 23% of
patients treated with NGT versus 38% of patients trea-
ted with LT (P = 0.89). Postoperative ileus averaged 6.1
days for NGT patients versus 4.6 days for LT patients
(P = 0.44).
Even the 2007 EAST guidelines on SBO management
[60] stated that there is no significant difference with
regard to the decompression achieved, the success of
nonoperative treatment, or the morbidity rate after sur-
gical intervention comparing long tube decompression
with the use of nasogastric tubes.
Nevertheless, in conservative treatment for challenging
cases of ASBO, the long tube should be placed as soon
as possible [61].
Early tube decompression, either with long intestinal
tube or just a naso-gastric tube, is therefore advisable in
the initial management of non strangulating ASBO, in
adjunct with fluid resuscitation and electrolytes imbal-
ances correction.
The first evidence of safety and efficacy of Water-
soluble contrast medium (Gastrografin) use in ASBO
was from Assalia et al. in the 90s [62]. The first pro-
spective RCT randomised 99 patients with partial ASBO
either to 100 ml of Gastrografin administered through
the nasogastric tube or conventional treatment. Mean
timing of the first stool was 23.3 hours in the control
group and 6.2 hours in the patients receiving Gastrogra-
fin (p < 0.00001). Ten obstructive episodes (21%) in the
control group required operative treatment compared
with six (10%) in the trial group (p = 0.12). Mean hospi-
tal stay for the patients who responded to conservative
treatment was 4.4 days and 2.2 days in the control and
trial groups, respectively (p < 0.00001). One patient in
each group died after operation. No Gastrografin-related
complications were observed.
A further update of this series including 127 patients
[63] not only confirmed the same findings in terms of
reduction of resolution of the obstruction and of the
hospital stay [mean time to first stool 6.2 hours vs 23.5
(p < .0001) and mean hospital stay for unoperated
patients 2.7 vs 5.5 days, (p < .0001)], but also showed as
well that significantly fewer episodes in the trial group
required operation, 10.4% vs 26.7% (p < 0.013).
Further evidence has been showed that the use of hyper-
osmolar Water-soluble contrast medium (Gastrografin) in
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servative treatment fails (after 48 hrs) and in patients
showing partial SBO. In the prospective RCT from Choi et
al. [64] the patients showing no clinical and radiologic
improvement in the initial 48 hours of conservative treat-
ment for non complicated ASBO were randomized to
undergo either Gastrografin meal and follow-through
study or surgery. Nineteen patients were randomized to
undergo Gastrografin meal and follow-through study and
16 patients to surgery.
Gastrografin study revealed partial obstruction in
14 patients. Obstruction resolved subsequently in all of
them after a mean of 41 hours. The other five patients
underwent laparotomy because the contrast study
showed complete obstruction. The use of Gastrografin
significantly reduced the need for surgery by 74%.
T h e r e f o r et h eu s eo fG a s t r o g r a f i ni nA S B Oi ss a f ea n d
reduces the need for surgery when conservative treat-
ment fails.
These results have been validated in a further study
where 44 episodes of ASBO showing no improvement
after 48 hours of conservative management received Gas-
trografin and out of them 7 underwent becuase of finding
of complete obstruction whereas Partial obstruction was
demonstrated in 37 other cases, obstruction resolved sub-
sequently in all of them except one patient who required
laparotomy because of persistent obstruction [65].
Biondo et al. demonstrated that water-soluble contrast
reduces the hospital stay but does not reduce the need
for surgery [66]. After randomizing 83 patients with 90
episodes of ASBO to either 100 ml of Gastrografin or
control, conservative treatment was successful in 77 epi-
sodes (85.6 per cent), among patients treated conserva-
tively hospital stay was shorter in the Gastrografin
group (P < 0.001) and all patients in whom contrast
medium reached the colon tolerated an early oral diet;
however Gastrografin did not reduce the need for opera-
tion (P = 1.000).
In another RCT 45 patients with ASBO were rando-
mized to receive either Gastrografin or placebo and 4
patients in each group required surgery but those who
received Gastrografin had complete resolution of their
ASBO significantly earlier than placebo patients (12 vs 21
h, P = 0.009) and this translated into a median of a 1-day
saving in time in hospital (3 vs 4 days, P = 0.03) [67].
A multicenter RCT from Di Saverio et al. [68] was the
first which clearly demonstrated a significant reduction of
the operative rate in patients with ASBO conservatively
managed with adjunct of hyperosmolar Water-soluble
contrast medium (Gastrografin), where has been showed a
significant reduction of the operative rate and the time to
resolution of obstruction, as well as the hospital stay.
Seventy-six patients were randomised to receiving tra-
ditional treatment or 150 ml Gastrografin meal via NGT
and follow-through study immediately. In the Gastrogra-
f i ng r o u po b s t r u c t i o nr e s o l v e ds u b s e q u e n t l yi n3 1o f
38 cases (81.5%) after a mean time of 6.4 hours. The
remaining seven patients were submitted to surgery, and
one of them needed bowel resection for strangulation.
In the control group, 21 patients were not submitted to
surgery (55%), whereas 17 showed persistent untreatable
obstruction and required laparotomy: 2 of them under-
went bowel resection for strangulation. The difference
in operative rate between the groups reached statistical
significance (p = 0.013). The time from the hospital
admission for obstruction to resolution of symptoms
was significantly lower in the Gastrografin group (6.4 vs.
43 hours; p < 0.01). The length of hospital stay revealed
a significant reduction in the Gastrografin group (4.7 vs.
7.8 days; p < 0.05). This reduction was more evident in
the subset of patients who did not require surgery (3 vs.
5.1 days; p < 0.01).
Again finally regarding the therapeutic value of Gastro-
grafin, the metanalysis from Abbas et al. (6 RCT included)
showed that Water-soluble contrast reduces the hospital
stay (weighted mean difference –1·84 days; P< 0·001) [69]
but does not reduce the need for surgery [70].
Nevertheless the most recent metanalysis from Branco
et al. [71], including overall 7 studies and having added
the most recent ones from 2008 and 2009, has proven
that WSCA administration is effective in both reducing
t h en e e df o rs u r g e r y( O R0 . 6 2 ;p = 0.007) and shorten-
ing hospital stay (WMD -1.87 days; p < 0.001), without
differences in complications and mortality.
Therefore we can confirm that Water soluble contrast
(Gastrografin) given in the setting of partial SBO can
improve bowel function (time to Bowel Movements),
decrease length of stay as well as it reduces the opera-
tive rate and is both therapeutic and diagnostic [72].
As further adjuncts needs to be mentioned that oral
therapy with magnesium oxide, L. acidophilus and
simethicone may hasten the resolution of conservatively
treated partial adhesive small bowel obstruction and
shorten the hospital stay [73]. In an RCT randomising
128 patients to either control group (intravenous hydra-
tion, nasogastric-tube decompression and nothing by
mouth) or intervention group (intravenous hydration,
nasogastric-tube decompression and oral therapy with
magnesium oxide, Lactobacillus acidophilus and
simethicone), more patients in the intervention group
than in the control group had successful treatment with-
out surgery (91% vs 76%, p = 0.03) and the mean hospi-
tal stay was significantly longer among patients in the
control group than among those in the intervention
group (4.2 vs 1.0 days, p < 0.001) without differences in
complication and recurrence rates.
Hyperbaric Oxygen therapy may be useful in manage-
ment of adhesive intestinal obstruction associated with
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to other conservative treatments. HBO therapy may be a
preferred option for treatment of patients for whom sur-
gery should be avoided [74].
Further matter of debate are how long should NOM be and
when it should be discontinued?
Usually NOM, in absence of signs of strangulation or
peritonitis, can be prolonged up to 72 hours of adhesive
SBO (Level of Evidence 2b GoR C)
After 3 days without resolution, WSCA study or sur-
gery is recommended (Level of Evidence 2b GoR C)
If ileus persists more than 3 days and the drainage
volume on day 3 is > 500 ml, surgery for ASBO is
recommended (Level of Evidence 2b GoR C)
With closely monitoring and in the absence of signs
suggestive of complications, an observation period even
longer than 10 days before proceeding to surgical inter-
vention appears to be safe [75].
However at any time, if onset of fever and leukocytosis
greater than 15 000/mm3 (predictors of intestinal com-
plications) are observed, then NOM should be discon-
tinued and surgery is recommended.
In the experience from the retrospective series of Cox
et al. [76], out of 123 patients initially managed with
conservative treatment, 31 of 38 patients requiring sur-
gical intervention for SBO, had so more than 48 h dura-
tion after admission and the difference between cases
resolving within 48 h and those requiring surgery after
48 h was significant (p< 0.001). Therefore most cases of
ASBO that will resolve, seem to do so within 48 h of
admission.
Fleshner et al. in their RCT comparing conservative
management of ASBO with NGT or LT, reported that,
between the 21 patients ultimately requiring operation,
the mean period between admission and operation was
60 hours in the NGT group versus 65 hours in the LT
group [77].
In a series of 35 patients with ASBO, a long intestinal
tube was endoscopically placed and the decompression
was successful in up to 90% of the cases [78]. Therefore
the authors recommend for patients with ASBO, a trial
with long tube decompression for 48 to 72 hours. For
those who fail a trial with the long tube, laparotomy
with enterolysis or bowel resection is indicated.
Contraindications to a trial with long tube decompres-
sion include strangulation obstruction, malignant
obstruction, incarcerated hernias, foreign body, radiation
enteritis, and peritonitis.
In a series of 53 patients with ASBO and treated with
long intestinal tube decompression, laparotomy is
appropriate after non-response for 7 and 3 days for
complete and partial SBO, respectively [79].
From further experiences, if ileus persists more than
3 days and the drainage volume on day 3 is > 500 ml,
surgery for ASBO is recommended [80].
The EAST practice management guidelines for SBO
recommend that patients without resolution of the SBO
by day 3-5 of non-operative management should
undergo water soluble study or surgery [81].
Finally when deciding between operative or non operative
management it would be beneficial to assess the risk of
ASBO recurrence after NOM and which factors can predict
recurrence of ASBO after NOM
The patients non responders to the long-tube and con-
servative treatment within 72 hours have a considerable
risk of recurrent ASBO (Level of Evidence 2b GoR C)
Risk factors for recurrences are age <40 years and
matted adhesion (Level of Evidence 1b GoR A)
Gastrografin use does not affect the recurrences rates
or recurrences needing surgery when compared to tradi-
tionally conservatively treated patients (Level of Evi-
dence 1b GoR A)
Out of 32,583 patients with an index admission for
SBO in 1997 from an US population study [82], 24%
had surgery during the index admission and regardless
of treatment during the index admission, 81% of surviv-
ing patients had no additional SBO readmissions over
the subsequent 5 years.
A prospective multicenter study including 286 patients
operated on for an adhesive postoperative SBO and fol-
lowed up for a median time of 41 months. The cumula-
tive incidence of overall recurrence was 15.9%, and for
surgically managed recurrence 5.8%. After multivariate
analysis, the risk factors for the overall recurrences were
age <40 years (hazard ratio HR, 2.97), adhesion or
matted adhesion (HR, 3.79) and, for the surgically mana-
ged: adhesions or matted adhesions (HR, 3.64), and
postoperative surgical complications (HR, 5.63) [83].
Non-operative treatment for adhesions in stable patients
results in a shorter hospital stay and similar recurrence
and reoperation rates, but a reduced interval to reobstruc-
tion when compared with operative treatment [84]. In
details patients treated without operation had a 34 per
cent readmission rate, compared with 32 per cent for
those treated surgically (P not significant), a shorter time
to readmission (median 0.7 versus 2.0 years; P < 0.05), no
difference in reoperation rate (14 versus 11 per cent; P not
significant) and fewer inpatient days over all admissions
(4 versus 12 days; P < 0.0001).
In retrospective series of 79 patients with ASBO, out
of 23 patients who recovered from ASBO following con-
servative treatment after 3 days with long intestinal
tubes, 16 patients showed recurrent ASBO and half
underwent surgery within 3 years [85].
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long-tube treatment within 72 hours have a significantly
higher chance of developing recurrent ASBO.
The same authors in a further study identified
91 patients who recovered from ASBO with nonopera-
tive management after long tube placement and divided
them into two groups for follow-up: the recurrence
group and the no-recurrence group [86] A significant
difference was found in the number of previous ASBO
admissions and the duration of long-tube placement
(77 hours vs. 43 hours). By multivariate analysis, the
duration of long-tube placement was an independent
parameter predicting the recurrence of ASBO. Therefore
the duration of long-tube placement might serve as a
parameter for predicting recurrence of ASBO in patients
managed with a long tube.
When addressing the association between type of
treatment (surgical versus conservative) and the risk of
recurrence, the results of a prospective study with long
term follow up showed that the risk of recurrence was
significantly lower in patients when the last ASBO epi-
sode was surgically treated than when it was nonsurgi-
cally treated (RR 0.55) [87]. Subanalyses showed that the
relative risk of being reoperated was the same regardless
of treatment method for the last episode (RR 0.79).
However, the relative risk of being readmitted for ASBO
without being operated was significantly lower for
patients treated surgically for their last ASBO episode
(RR 0.42).
In the series from Williams et al. [88] the frequency of
recurrence for those treated nonoperatively was 40.5%
compared with 26.8% for patients treated operatively
(P < 0.009). Patients treated without operation had a sig-
nificantly shorter time to recurrence (mean, 153 vs. 411
days; P < 0.004) and had fewer hospital days for their
index small bowel obstruction (4.9 vs. 12.0 days; P <
0.0001). However there was no significant difference
between early and late recurrent small bowel obstruc-
tion in patients treated nonoperatively or operatively,
regardless of prior history of abdominal surgery. Logistic
regression analysis failed to identify any specific risk fac-
tors that were predictors of the success of conservative
or surgical management.
The use of Gastrografin does not seem to affect the
recurrence rate or speeding up the recurrence after conser-
vatively treated ASBO. In a multicenter RCT, no significant
differences in the relapse rate were found when compared
to traditional conservative treatment (relapse rate, 34.2%
after a mean time to relapse of 6.3 months in the Gastro-
grafin group vs. 42.1% after 7.6 months; p =n s )[ 8 9 ] .
- Surgical Treatment: Open and Laparoscopic approach
After 3 days of NOM without resolution of ASBO
surgery is recommended (LOE 2c GoR C)
If ileus persists more than 3 days and the drainage
volume on day 3 is > 500 ml, surgery for ASBO is
recommended (Level of Evidence 2b GoR C)
Also when fever and leukocytosis level (> 15 000/
mm3) rises anytime during the course, then surgery is
advised GoR C
Open surgery is the preferred method for the surgical
treatment of strangulating ASBO and afte failed conser-
vative management (LOE 2c GOR C)
In highly selected group of patients the laparoscopic
can be attempted using an open access technique (LOE
2c GOR C)
The access in the left upper quadrant should be safe
(LOE 4 GOR C)
Laparoscopic lysis of adhesions should be attempted
preferably in case of first episode of SBO and/or antici-
pated single band adhesion (i.e. SBO after appendect-
omy or hysterectomy) (LOE 3b GOR C)
A low threshold for open conversion should be main-
tained if extensive adhesions are found (LOE 2c GOR C)
Conversion to laparoscopic-assisted adhesiolysis (mini-
laparotomy with an incision less than 4 cm long) or
laparotomy should be considered in those patients pre-
senting with dense or pelvic adhesion (LOE 3b GOR C)
The extent of adhesiolysis is a matter still under
debate. The approaches to adhesiolysis for bowel
obstruction among general surgeons in the United King-
dom were established in 1993 [90]. Half of all surgeons
divided all adhesions to prevent recurrence of bowel
obstruction, whereas the other half limited adhesiolysis
to only the adhesions responsible for the obstruction.
Adhesions are less after transverse or Pfannenstiel
incision in comparison to midline incisions and after
surgery for obstetric compared with gynaecological indi-
cations [91]. The risk of anterior abdominal wall adhe-
sions increases with the number of previous
laparotomies although this relationship is not as evident
as the relationship between previous laparotomies and
adhesiolysis-induced enterotomy [92,93].
In a prospective study of 1791 patients undergoing
benign colorectal surgery (n = 1701) or surgery for
small bowel obstruction (n = 90) with 89% having base-
line adhesions, the mean time to lyse adhesions was
34 min ranging from 1 to 240 min [94]. Mean time
required for lysis of adhesions was about one-fifth of
total mean operative time. Notably, 34% of patients had
no previous abdominopelvic surgery and presented non-
surgical adhesions resulting from intra-abdominal
inflammatory and infectious processes associated with
benign colorectal diseases including diverticulitis,
Crohn’s disease and ulcerative colitis.
Higher age and higher number of previous laparo-
tomies appeared to be predictors of the occurrence
of inadvertent enterotomy [95]. Patients with three or
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enterotomy compared with patients with one or two
previous laparotomies strongly suggesting more dense
adhesion reformation after each reoperation
Historically, laparotomy and open adhesiolysis have
been the treatment for patients requiring surgery for
small bowel obstruction. Unfortunately, this often leads
to further formation of intraabdominal adhesions with
approximately 10% to 30% of patients requiring another
laparotomy for recurrent bowel obstruction [96].
In animal models laparoscopy has been shown to
decrease the incidence, extent, and severity of intraab-
dominal adhesions when compared with open surgery,
thus potentially decreasing the recurrence rate for adhe-
sive small bowel obstruction [97].
Laparoscopy seems to have an advantage above lapar-
otomy in terms of adhesion formation to the abdominal
wall and to the operative site [98,99].
Laparoscopic adhesiolysis for small bowel obstruction
has a number of potential advantages: (1) less post-
operative pain, (2) quicker return of intestinal function,
(3) shorter hospital stay, (4) reduced recovery time,
allowing an earlier return to full activity, (5) fewer
wound complications, and (6) decreased postoperative
adhesion formation [100].
However No randomized controlled trial comparing
open to laparoscopic adhesiolysis exists up to date, and
both the precise indications and specific outcomes of
laparoscopic adhesiolysis for adhesive SBO remain
poorly understood. The only RCT on laparoscopic adhe-
siolysis assessed the incidence of chronic abdominal
pain after randomization to laparoscopic adhesiolysis or
no treatment during diagnostic laparoscopy and it failed
to demonstrate any significant differences in terms of
pain or discomfort [101].
Although data from retrospective clinical controlled
trials suggest that laparoscopy seems feasible and better
in terms of hospital stay and mortality reduction, high
quality randomised controlled trials assessing all clini-
cally relevant outcomes including overall mortality, mor-
bidity, hospital stay and conversion are lacking [102].
Although the adhesiolysis hospitalization rate has
remained constant in USA since 1988, inpatient expen-
ditures have decreased by nearly 10% because of a 15%
decrease in the average length of stay (from 11.2 days in
1988 to 9.7 days in 1994) [103]. From this large popula-
tion Hospital Discharge reports Survey, is derived that
laparoscopic less invasive surgical techniques for adhe-
siolysis, increased over the last years, have contributed
to the decreased time required in the hospital for both
the surgical procedure itself and the recovery time.
However the increased use of laparoscopy during this
study period did not appear to be associated with a con-
comitant reduction in the adhesiolysis hospitalization
rate therefore a common denominator may exist
between surgical trauma and immune response to for-
eign bodies.
When deciding between an open or laparoscopic
approach, the first consideration is that the surgeon be
trained and capable of performing advanced laparo-
scopy. With regards to patient selection, patients with
an acute small bowel obstruction and peritonitis or free
air requiring an emergent operation are best managed
with a laparotomy. Patients without peritonitis who do
not resolve with nonoperative management should be
considered for laparoscopic adhesiolysis. In these cases,
it is important to consider the bowel diameter, degree of
abdominal distention, and location of the obstruction
(ie, proximal or distal). Suter et al [104] found that a
bowel diameter exceeding 4 cm was associated with an
increased rate of conversion: 55% versus 32% (p =0 . 0 2 ) .
Patients with a distal and complete small bowel obstruc-
tion have an increased incidence of intraoperative com-
plications and increased risk of conversion. Patients with
persistent abdominal distention after nasogastric intuba-
tion are also unlikely to be treated successfully with
laparoscopy.
The influence of dense adhesions and the number of
previous operations on the success of laparoscopic adhe-
siolysis is controversial. León et al state that a documen-
ted history of severe or extensive dense adhesions is a
contraindication to laparoscopy [105]. Navez et al [106]
found that patients who had only a previous appendect-
o m yw e r em o s tl i k e l yt ob es u c c e s s f u l l ym a n a g e dw i t h
laparoscopy. In contrast, Suter et al found no correlation
between the number and or type of previous surgeries
and the chance of a successful laparoscopic surgery
[107]. Other factors such as an elevated white blood cell
count or a fever have not been demonstrated to corre-
late with an increased conversion rate [Suter et al.,
Navez et al.]. One group of patients who are good can-
didates for laparoscopic adhesiolysis are those with a
nonresolving, partial small bowel obstruction or a recur-
rent, chronic small bowel obstruction demonstrated on
contrast study [108,109].
In a recent series of 46 patients [110], best results in
terms of success rate (91,3%) and no intraoperative
bowel perforations, with a relapse free rate of 93,5%
after a mean follow up of 46,5 months, can be achieved
with the laparoscopic approach when it is used for sub-
groups of patients with recurrent SBO after abdominal
or pelvic surgery, scheduled for elective adhesiolysis, or
if the laparoscopic intervention is performed early when
the patient had failed to respond to 24 hrs of conserva-
tive treatment from the onset of acute SBO.
Perforated or gangrenous bowel is best managed with
conversion to either a minilaparotomy or a formal lapar-
otomy. Matted small bowel loops and dense adhesions
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et al reported that only 10% of obstructions caused by
dense adhesions could be treated successfully with
laparoscopy. On the other hand, when the cause of
obstruction was a single band, laparoscopic adhesiolysis
was successful 100% of the time [111].
When other etiologies are found, such as internal her-
nia, inguinal hernia, neoplasm, inflammatory bowel dis-
ease, intussusception, and gallstone ileus, conversion to
a minilaparotomy or a formal laparotomy is required.
Inadvertent enterotomy during reopening of the abdo-
men or subsequent adhesion dissection is a feared com-
plication of surgery after previous laparotomy. The
incidence can be as high as 20% in open surgery and
between 1% and 100% in laparoscopy [112].
The incidence of intraoperative enterotomies during
laparoscopic adhesiolysis ranges from 3% to 17.6%, with
most authors reporting an incidence of about 10%
[113,114]. Suter et al reported an intraoperative enterot-
omy incidence of 15.6%, of which 62% were repaired
laparoscopically. One of the most dreaded complications
of surgery is a missed enterotomy. Although a missed
enterotomy can occur after laparotomy, the incidence is
higher after laparoscopic surgery. Again Suter et al
r e p o r t e d4o f4 7c a s e s( 8 . 5 % )o fm i s s e de n t e r o t o m i e s
requiring reoperation.
The long-term results regarding recurrence are lim-
ited, with most series reporting a mean follow-up
between 12 and 24 months. Navez et al reported that
85% (29 of 34) of the patients treated laparoscopically
were asymptomatic with a mean follow-up of 46
months. The series with the longest follow-up (mean
61.7 months) reported 87.5% (14 of 16) of the patients
treated laparoscopically were asymptomatic [115].
Feasibility of diagnostic laparoscopy is ranging from
60% to 100% whilst therapeutic effectiveness of the
laparoscopic approach is lower (40-88%). Predictive fac-
tors for successful laparoscopic adhesiolysis are: number
of previous laparotomies ≤2, non-median previous lapar-
otomy, appendectomy as previous surgical treatment
causing adherences, unique band adhesion as phatoge-
netic mechanism of small bowel obstruction, early
laparoscopic management within 24 hours from the
onset of symptoms, no signs of peritonitis on physical
examination, experience of the surgeon [116].
Surgical operating time is greater in patients who
underwent laparoscopic surgery compared to patients
who underwent a laparotomy [117,118]. However the
duration of laparoscopic procedure is variable ranging
from 20 minutes for a simple band adhesion to 2-3
hours for more complex cases [119,120]. Postoperative
morbidity is lower in patients who underwent laparo-
scopic adhesiolysis compared to those who underwent
the laparotomic approach. Furthermore a greater rate of
morbidity is present in patients who underwent laparo-
tomic conversion; whereas mortality is comparable in
the two groups (0-4%). Finally the laparoscopic adhesio-
lysis can avoid laparotomy, which is itself a cause of
new adhesions and bowel obstruction, although some
authors noticed a greater incidence of recurrent small
bowel obstructions in patients who underwent laparo-
scopy compared to those in which a laparotomy was
performed [121-124].
In a large review of 308 patients from 35 centres [125]
over 8 years the ‘successful’ laparoscopy rate was 54.6%
and the conversion to laparotomy rate was 45.4%. There
were significantly more successes among patients with a
history of one or two laparotomies than among those
with three or more (56% vs 37%; p < 0.05). Furthermore
t h er a t eo fs u c c e s sw a ss i g n i f i c a n t l yh i g h e r( p <0 . 0 0 1 )
in patients operated on early (<24 h) and in patients
with bands (54%), than in those with matted adhesions
(31%).
In a French experience the laparoscopic approach,
with a conversion rate of 31%, did not show any influ-
ence on the early postoperative mortality (P =. 7 )n o r
on morbidity (P = .4) [126].
Although a laparoscopic approach has been proposed
to decrease the incisional trauma and to lower the rate
of recurrence, a slightly higher but nonstatistically sig-
nificant rate of recurrences in the laparoscopic approach
has been observed. Probably, further several different
even smaller incisions and a mandatory identical parietal
and visceral adhesiolysis as laparotomy do not decrease
the magnitude of the peritoneal trauma [127].
The largest and most significant large population
review from US identified from the 2002 National Inpa-
tient Sample 6,165 patients with intestinal obstruction
undergoing open (OLA) and laparoscopic lysis of adhe-
sions (LLA) [128]. 88.6% underwent OLA and 11.4%
had LLA. Conversion was required in 17.2% of LLA
patients. Unadjusted mortality was equal between LLA
a n dc o n v e r s i o n( 1 . 7 % )a n dh a l ft h er a t ec o m p a r e dw i t h
OLA (3.4%) (p = 0.014). The odds of complications in
the LLA group (intention to treat) were 25% less than in
the OLA (p = 0.008). The LLA group had a 27% shorter
LOS (p = 0.0001) and was 9% less expensive than the
OLA group (p = 0.0003). There was no statistical signifi-
cant difference for LOS, complications, and costs
between the conversion and OLA groups.
The comparably low conversion rate of 17% by Man-
cini et al. in this study may be explained by the low
initial percentage (11%) of patients treated laparoscopi-
cally, indicating a positive selection of patients amenable
to successful laparoscopic adhesiolysis.
Szomstein and colleagues [129] summarized data on
conversion rates for laparoscopic lysis of adhesions and
reported a range from 6.7% to 41%. The benefits and
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sions are highlighted in this review of 11 series includ-
ing 813 patients. They have found that 63% of the
length of a laparotomy incision is involved in adhesion
formation to the abdominal wall. Furthermore, the inci-
dence of ventral hernia after a laparotomy ranges
between 11% and 20% versus the 0.02%-2.4% incidence
of port site herniation. Additional benefits of the mini-
mally invasive approaches include a decreased incidence
of wound infection and postoperative pneumonia and a
more rapid return of bowel function resulting in a
shorter hospital stay. In long-term follow up, the success
rate of laparoscopic lysis of adhesions remains between
46% and 87%. Operative times for laparoscopy range
from 58 to 108 minutes; conversion rates range from
6.7% to 43%; and the incidence of intraoperative enter-
otomy ranges from 3% to 17.6%. The length of hospitali-
zation is 4-6 days in most series. In this review again
contraindications to the min i m a l l yi n v a s i v et e c h n i q u e
include the following: (1) massive abdominal distension
that precludes entry into the peritoneal space and limits
adequate working space; (2) the presence of peritonitis
with the need for bowel resection and bowel handling in
ah i g h l yi n f l a m e de n v i r o n ment; (3) hemodynamic
instability; (4) severe comorbid conditions such as heart
and lung diseases that preclude the use of pneumoperi-
toneum; and (5) finally, but certainly not the least
important, the surgeon’s comfort level.
An interesting although small review of 93 patients
with ASBO from a community teaching hospital [130],
divided into successful laparoscopy (66 patients [71%]),
secondary conversion (24 [26%]), and primary laparot-
omy (three patients), showed that patients with successful
laparoscopy had more simple adhesions (57%), fewer
prior operations, and lower ASA class. Operative time
was shortest in the laparoscopy group (74.3 ± 4.4 min),
as was the duration of both intensive care unit and hospi-
tal stay. Mortality was 6%, regardless of operative tech-
nique. The author’s conclusion confirmed that the
parameters associated with successful laparoscopic man-
agement of SBO are the presence of isolated bands, lower
ASA scorse, younger age, fewer prior operations, and a
shorter duration of SBO obstruction before the opera-
tion. Reasons for primary laparotomy included a state of
prolonged ileus with progressive abdominal distension
and a higher number or more extensive previous opera-
tions. Reasons for converting to open adhesiolysis follow-
ing initial laparoscopy were inadequate laparoscopic
control due to intestinal distension, extensive adhesions,
iatrogenic intestinal perforation and the presence of
necrotic segments of the small bowel upon initial laparo-
scopy, requiring secondary open resection.
Zerey et al. [131] reported a series of 33 patients
underwent laparoscopic adhesiolysis secondary to a
SBO. Twenty-nine patients (88%) were successfully
treated laparoscopically. Mean procedural time was
101 minutes (range, 19-198 minutes). Only one patient
had a recurrent SBO 8 months postoperatively managed
by repeat laparoscopic lysis of adhesions. Mean post-
operative stay was 6 days.
In another report of 65 patients submitted to laparo-
scopic adhesiolysis (40 for acute obstruction and 25 for
chronic or recurrent transit disturbances) the procedure
was completed by laparoscopy in 52 patients (conversion
rate: 20%) and after a mean follow up of 48 months has
been observed a 15.4% rate of symptomatic recurrences,
while surgical recurrences have been 4.6% [132].
In a series of 17 patients scheduled for elective adhe-
siolysis [133], laparoscopic treatment was successful in
14 patients (82.4%) and two recurrences of small bowel
obstructions were noted over a mean follow-up period
of 61.7 months. In a similar series of elective laparo-
scopic treatment of 25 patients with recurrent small
bowel obstruction, complete laparoscopic adhesiolysis
was feasible in 18 patients (72%) and no recurrence of
small bowel obstruction over a mean follow-up period
of 41 months have been observed [134]. In this series
conversion to laparoscopic-assisted adhesiolysis (mini-
laparotomy with an incision less than 4 cm long) was
required in 6 patients (24%) because of dense adhesion
or the technical difficulties due to adhesion in the pelvic
cavity.
Leon et al. reported a 35% co n v e r s i o nr a t ei nas e r i e s
of 40 patients and at median follow-up of 12 months,
21 of 26 patients managed laparoscopically or with
laparoscopic-assisted procedures remained asympto-
matic [135].
A review in 2007 show that laparoscopic management
of SBO is successful in 66% of patients with a conver-
sion rate of 33.5% [136].
Operative technique has capital role for a successful
laparoscopic treatment [137]. The initial trocar should
be placed away (alternative site technique) from the
scars in an attempt to avoid adhesions. Some investiga-
tors have recommended the use of computed tomogra-
phy scan or ultrasonography to help determine a safe
site for the initial trocar insertion.
T h el e f tu p p e rq u a d r a n ti so f t e nas a f ep l a c et og a i n
access to the abdominal cavity. Alternatively a 10 mm
port can be inserted in the left flank with two additional
5 mm ports in the left upper and lower quadrant.
Therefore, by triangulating 3 ports aimed at the right
lower quadrant, a good exposure and access to the right
iliac fossa can be obtained and a technique running the
small bowel in a retrograde fashion, starting from the
ileocecal valve (decompressed intestine) proximally
towards the transition point between collapsed and
dilated loops.
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more prudent. Once safe access is obtained, the next
goal is to provide adequate visualization in order to
insert the remaining trocars. This often requires some
degree of adhesiolysis along the anterior abdominal wall.
Numerous techniques are available, including finger dis-
section through the initial trocar site and using the cam-
era to bluntly dissect the adhesions. Sometimes, gentle
retraction on the adhesions will separate the tissue
planes. Most often sharp adhesiolysis is required. The
use of cautery and ultrasound dissection should be lim-
ited in order to avoid thermal tissue damage and bowel
injury.
Strickland have reported an incidence of 10% entero-
tomies during exploration and adhesiolysis in 40 patients
treated laparoscopically for acute SBO. However an even
higher proportion of the patients had enterotomies after
conversion (23%) [138]. Furthermore formal laparotomy
was avoided in 68% of these patients and earlier return of
bowel function and a shorter postoperative length of stay,
with lower overall costs was achieved with laparoscopic
treatment. The risk of enterotomy can be reduced if
meticulous care is taken in the use of atraumatic graspers
only and if the manipulation of friable, distended bowel
is minimized by handling the mesentery of the bowel
whenever possible. In fact to handle dilated and edema-
tous bowel during adhesiolysis is dangerous and the risk
increases with a long lasting obstruction; therefore early
operation is advisable as one multicenter study showed
that the success rate for early laparoscopic intervention
for acute SBO was significantly higher after a shorter
duration of symptoms (24 h vs 48 h) [139].
Maintaining a low threshold for conversion to laparot-
omy in the face of extensive adhesions will further
decrease the risk of bowel injury.
After trocar placement, the initial goal is to expose the
collapsed distal bowel. This is facilitated with the use of
angled telescopes and maximal tilting/rotating of the
surgical table. It may also be necessary to move the
laparoscope to different trocars to improve visualization.
If necessary, the small bowel mesentery (instead of the
bowel wall) should be grasped in order to manipulate
the bowel. Sharp dissection with the laparoscopic scis-
sors should be used to cut the adhesions. Only patholo-
gic adhesions should be lysed. Additional adhesiolysis
only adds to the operative time and to the risks of sur-
gery without benefit. The area lysed should be thor-
oughly inspected for possible bleeding and bowel injury.
In conclusion, careful selection criteria for laparoscopy
[140] may be: (1) proximal obstruction, (2) partial
obstruction, (3) anticipated single band, (4) localized dis-
tension on radiography, (5) no sepsis, (6) mild abdom-
inal distension and last but not least (7) the experience
and laparoscopic skills of the surgeon.
The experts panel also agreed, as from the cited stu-
dies, that laparoscopic lysis of adhesions should be
a t t e m p t e dp r e f e r a b l yi nc a s eo ff i r s te p i s o d eo fS B O
and/or anticipated single band adhesion (i.e. SBO after
appendectomy or hysterectomy).
Furthermore the experts highlighted that an open port
access should be attempted, and gaining the access in
the left upper quadrant should be safe. However a large
consensus has been reached in recommending a low
threshold for open conversion if extensive adhesions are
found.
- Prevention
We do need to prevent ASBO (LOE 2b GoR B)
Hyaluronic acid-carboxycellulose membrane and ico-
dextrin are able to reduce adhesions (respectively LOE
1a GOR A and LOE 1b GOR A).
Icodextrin may reduce the risk of re-obstruction for
ASBO (LOE 1 b GOR A).
Hyaluronic acid-carboxycellulose can not reduce the
need of surgery for ASBO (LOE 1a GOR A).
A systematic review including a total of 446,331
abdominal operations found an overall incidence of SBO
of 4.6% [141]. The risk of SBO was highly influenced by
the type of procedure, with ileal pouch-anal anastomosis
being associated with the highest incidence of SBO
(19.3%), followed by open colectomy (9.5%). Gynecologi-
cal procedures were associated with an overall incidence
of 11.1% and ranged from 23.9% in open adnexal sur-
gery to 0.1% after cesarean section.
Adhesions and ASBO are extremely common and the
cumulative recurrence rate for patients operated once
for ASBO is 18% at 10 years and 29% at 30 years as
shwon in a long term follow up cohort study. Cumula-
tive recurrence rate reaches 81% for patients with 4 or
more admissions [142].
Another multicer prospective study [143] showed that
the cumulative incidence of overall recurrence of ASBO
was 15.9% after a median follow up of 41 months and
for surgically managed recurrences it was 5.8%. There-
fore, in view of the incidence of adhesions and recur-
rence rates of ASBO as well as of the magnitude of the
medical problems and financial burden related to adhe-
sions, prevention or reduction of postoperative adhe-
sions in an important priority. Even though awareness
of this problem is widely agreed among surgeons and
gynaecologists, uncertainty still exists about the treat-
ment and prophylactic strategies for dealing with adhe-
sions [144]. A recent national survey among Dutch
surgeons and surgical trainees [145] showed that under-
estimation of the extent and impact of adhesions
resulted in low knowledge scores and Lower scores cor-
related with more uncertainty about indications for anti-
adhesive agents which, in turn, correlated with never
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adhesion barriers have been published but several con-
troversies such as the effectiveness of available agents
and their indication in general surgical patients still
e x i s t .M o s to ft h ea v a i l a b l el i t e r a t u r ei sb a s e do ng y n e -
cologic patients. For general surgical patients no recom-
mendations or guidelines exist.
Any prevention strategy should be safe, effective, prac-
tical, and cost effective. A combination of prevention
strategies might be more effective [146].
The prevention strategies can be grouped into 4 cate-
gories: general principles, surgical techniques, mechani-
cal barriers, and chemical agents.
General principles
Intraoperative techniques such as avoiding unnecessary
peritoneal dissection, avoiding spillage of intestinal con-
tents or gallstones [147], and the use of starch-free
gloves [148,149] are basic principles that should be
applied to all patients. In a large systematic review
[150], the closure of the peritoneum, spillage and reten-
tion of gallstones during cholecystectomy, and the use
of starched gloves all seems to increase the risk for
adhesion formation.
Surgical techniques
The surgical approach (open vs laparoscopic surgery)
plays an important role in the development of adhesive
SBO.
In the long term follow up study from Fevang et al.
[151] the surgical treatment itself decreased the risk of
future admissions for ASBO, even though the risk of
new surgically treated ASBO episodes was the same
regardless of the method of treatment (surgical vs
conservative).
The technique of the procedure (open vs. laparoscopic)
also seems to play a major role in the development of
adhesive SBO. The incidence was 7.1% in open cholecys-
tectomies vs. 0.2% in laparoscopic; 15.6% in open total
abdominal hysterectomies vs. 0.0% in laparoscopic; and
23.9% in open adnexal operations vs. 0.0% in laparo-
scopic. There was no difference in SBO following laparo-
scopic or open appendectomies (1.4% vs. 1.3%) [152].
In most abdominal procedures the laparoscopic
approach is associated with a significantly lower inci-
dence of adhesive SBO or adhesion-related re-admission.
In a collective review of the literature the incidence of
adhesion-related re-admissions was 7.1% in open versus
0.2% in laparoscopic cholecystectomies, 9.5% in open
versus 4.3% in laparoscopic colectomy, 15.6% in open
versus 0% in laparoscopic total abdominal hysterectomy,
and 23.9% in open versus 0% in laparoscopic adnexal
surgery. Only in appendectomies there was no difference
between the two techniques [153].
There is some class I evidence in obstetrics supporting
the theory that suturing the peritoneum increases the
risk of adhesions [154]. It is therefore prudent to avoid
peritoneal closure during laparotomies.
Mechanical barriers
In theory, inert materials that prevent contact between
the damaged serosal surfaces for the first few critical
days allow separate healing of the injured surfaces and
may help in the prevention of adhesion formation. Var-
ious bioabsorbable films or gels, solid membranes, or
fluid barrier agents have been tested experimentally and
in clinical trials.
Hyaluronic acid/carboxymethylcellulose (Seprafilm) is
the most extensively tested adhesion prevention agent in
general surgery. Its safety with regard to systemic or
specific complications has been established in many stu-
dies, including a safety study of 1,791 patients with
abdominal or pelvic surgery, however there are concerns
about a higher incidence of anastomotic leaks in cases
in which the film is placed directly around the anasto-
mosis [155].
Several prospective randomized controlled trials
showed efficacy in reducing the incidence and extent of
postoperative adhesions. In a prospective, randomized,
multicenter, double-blind study of 175 evaluable patients
with colectomy and ileoanal pouch procedure, compared
Seprafilm with controls, The Seprafilm group had signif-
icantly fewer and less severe adhesions and well as of
reduced extent [156].
A further prospective multicenter study, randomized
71 patients undergoing Hartmann’s resection into a
Seprafilm and a control group: although the incidence
of adhesions did not differ significantly between the
study groups, the Seprafilm group showed a significant
reduction of the severity of adhesions [157].
Cohen et al, in a prospective multicenter trial, rando-
mized 120 patients with colectomy and ileal pouch sur-
geries into a Seprafilm and a control group [158]. The
outcomes included incidence and severity of adhesions
and were assessed laparoscopically by a blinded observer
at a second surgery 8 to 12 weeks later for ileostomy
closure. Treatment with Seprafilm significantly reduced
the incidence and severity of adhesions.
Kumar et al in a recent Cochrane collective review of
6r a n d o m i z e dt r i a l sw i t hn ongynecologic surgical
patients found that Seprafilm significantly reduced the
incidence of adhesions (OR, .15; 95% CI, .05-.43; P <
.001) and the extent of adhesion (mean difference,
–25.9%; 95% CI, –40.56 to –11.26; P < .001) [159].
A l t h o u g ht h e r ei ss a t i s f a c t o r yc l a s sIe v i d e n c et h a t
Seprafilm significantly reduces the incidence and sever-
i t yo fp o s t o p e r a t i v ea d h e s i o n s ,t h e r ei sf a i r l yl i m i t e d
work on the effect of this adhesion reduction on the
incidence of SBO.
Fazio et al in a prospective, randomized, multicenter,
single-blind study of 1,791 patients with intestinal
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vention. There was no difference between the Seprafilm
and control group in the overall incidence of SBO (12%
vs 12%). However, the incidence of SBO requiring surgi-
cal intervention was significantly lower in the Seprafilm
group (1.8% vs 3.4%; P <. 0 5 ) .T h i sw a sa na b s o l u t e
reduction of 1.6% and a relative reduction of 47%. Step-
wise multivariate analysis showed that the use of Sepra-
film was the only independent factor for reducing SBO
requiring reoperation [160].
Kudo et al in a nonrandomized study of 51 patients
who underwent transabdominal aortic aneurysm sur-
gery, analyzed the incidence of early SBO in patients
who had Seprafilm applied and in control patients with
no treatment. The incidence of early SBO was 0% in
the Seprafilm group and 20% in the control group (P <
.05) [161].
A dutch RCT including 71 patients requiring a Hart-
mann procedure for sigmoid diverticulitis or obstructed
rectosigmoid were randomized to either intraperitoneal
placement of the antiadhesions membrane under the
midline during laparotomy and in the pelvis, or as a
control [162].
The incidence of adhesions did not differ significantly
between the two groups, but the severity of adhesions
was significantly reduced in the Seprafilm group both
for the midline incision and for the pelvic area. Compli-
cations occurred in similar numbers in both groups.
A recent systematic Review and Meta-analysis [163]
including 4203 patients showed that incidence of grade
0 adhesions among Seprafilm-treated patients was statis-
tically significantly more than that observed among con-
trol group patients. There was no significantd i f f e r e n c e
in the incidence of grade 1 adhesions between Seprafilm
and control groups. The severity of grade 2 and grade 3
adhesions among Seprafilm-treated patients was signifi-
cantly less than that observed among control group
patients. The incidence of intestinal obstruction after
abdominal surgery was not different between Seprafilm
and control groups. Using Seprafilm significantly
increased the incidence of abdominal abscesses and ana-
stomotic leaks.
I naC o c h r a n er e v i e wo f7R C T ,s i xc o m p a r e dh y a -
luronic acid/carboxymethyl membrane (HA/CMC) and
one 0.5% ferric hyaluronate gel against controls. HA/
CMC reduced the incidence of adhesions with reduced
extent and severity [164]. However there was no reduc-
tion of intestinal obstruction needing surgical interven-
tion with comparable overall morbidity and mortality.
The study of 0.5% ferric hyaluronate gel was prema-
turely terminated and no valid conclusions could be
made but there was a higher incidence of overall mor-
bidity and ileus. Therefore authors’ conclusions were
that the use of HA/CMC membrane reduces incidence,
extent and severity of adhesions which may, theoreti-
cally, have implications in re-operative abdominal sur-
gery. There is no evidence that the incidence of
intestinal obstruction or need for operative intervention
is reduced. HA/CMC appears to be safe but there may
be a risk of leak when wrapped around an anastomoses.
Oxidized regenerated cellulose (Interceed) is a
mechanical barrier that forms a gelatinous protective
coat and breaks down and is absorbed within 2 weeks.
This product has been studied in numerous prospective
randomized studies in open or laparoscopic gynecologic
surgeries. It has been shown to be safe and effective in
reducing adhesions. The first study was a prospective,
randomized, multicenter, clinical trial that evaluated the
efficacy of Interceed in reducing adhesions in humans
[165]. Infertility patients (n = 74) with bilateral pelvic
sidewall adhesions were studied at treatment laparotomy
and “second-look” laparoscopy to determine Interceed’s
effectiveness. It did show a significant reduction of
incidence, extent, and severity of postsurgical pelvic
adhesions.
In the second prospective, randomized, controlled
clinical study, 21 women underwent a second-look
laparoscopy 2-11 weeks after standardized laparoscopic
electrosurgical treatment for polycystic ovarian syn-
drome [166]. Following bilateral ovarian treatment, one
ovary was randomly chosen to have Interceed applied to
its surface using a specially designed applicator, with the
other ovary serving as a control. Peri-adnexal adhesions
of significant extent and severity developed in 57% of
the women and 38% of the adnexa. The incidence of
adhesions on the Interceed-treated side was 43%, while
on the control side it was 33%. In addition, the extent
and severity of the adhesions appeared to be similar on
the Interceed-treated and control side.
In a prospective randomized study of 134 women
undergoing adhesiolysis by laparotomy, and having
applied Interceed on one sidewall and left the opposite
side uncovered, the incidence and severity of adhesions
were evaluated at a second-look laparoscopy 10 days to
14 weeks after surgery and Interceed significantly
reduced the incidence and extent of adhesions [167].
The Nordic Adhesion Prevention Study group in a mul-
ticenter, prospective, randomized, blinded study of 66
women undergoing adhesiolysis of 132 ovaries used
Interceed around the adnexa on one side and left the
other side uncovered. The incidence and severity of
adhesions were assessed at a second-look laparoscopy 4
to 10 weeks after the initial surgery and the results
showed that Interceed significantly reduced the inci-
dence, extent, and severity of adhesions [168]. A meta-
analysis of 7 randomized studies showed that Interceed
decreased the incidence of adhesions by 24.2% ± 3.3%
(P < .001) when compared with untreated sites [169]. A
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reduced the incidence and severity of adhesions after
open or laparoscopic gynecologic surgery [170].
Expanded polytetrafluoroethylene (Gore-Tex, Pre-
clude; W.L. Gore & Associates, Hertogenbosch, The
Netherlands): It is an inert, nonabsorbable permanent
membrane that needs to be removed a few days after
application. It has been studied mainly in gynecologic
surgeries with favorable results [171]. Its usefulness is
limited because of the need to be removed surgically at
a later stage.
Various Bioabsorbable gels have been developed and
tested, but most have been abandoned or withdrawn
because of safety issues or a lack of efficacy. SprayGel is
a sprayable hydrogel that adheres to the tissues for a
period of 5 to 7 days. After several days it is hydrolyzed
into water-soluble molecules and is absorbed. Safety of
SprayGel has been shown in a few gynecologic and col-
orectal studies, however although early preliminary clini-
cal trials showed its effectiveness, a larger-scale study
was stopped owing to a lack of efficacy [172].
Finally a systematic review of barrier agents for adhe-
sion prevention after gynaecological surgery assessed the
effect of physical barriers used during pelvic surgery in
women of reproductive age on pregnancy rates, pelvic
pain, or postoperative adhesion reformation [173]. The
authors’ conclusions were that the absorbable adhesion
barrier Interceed reduces the incidence of adhesion for-
mation following laparoscopy and laparotomy. Gore-Tex
may be superior to Interceed in preventing adhesion for-
mation but its usefulness is limited by the need for
suturing and later removal. There was no evidence of
effectiveness of Seprafilm and Fibrin sheet in preventing
adhesion formation.
Chemical/Fluid agents
Fluid agents have the theoretical advantage of covering
more potential sites of adhesion formation than
mechanical barriers.
A systematic review updated at 2006 [174], regarding
fluids and pharmacological agents for adhesion preven-
tion after gynaecological surgery, found insufficient evi-
dence for the use of the following agents: steroids,
icodextrin 4%, SprayGel and dextran in improving adhe-
sions following surgery. There was some evidence that
hyaluronic acid agents may decrease the proportion of
adhesions and prevent the deterioration of pre existing
adhesions but the need of further studies was advocated.
The most widely studied and the only Food and Drug
Administration-approved adhesion-prevention fluid
agent in laparoscopic surgery is Adept (Baxter Health-
care, Deerfield, IL). Adept (icodextrin 4% solution) is
used as an irrigant fluid throughout surgery and at the
end of surgery 1,000 mL is instilled and left in the peri-
toneal cavity. The fluid remains in the peritoneal cavity
for several days and separates the damaged surfaces dur-
ing the critical period of adhesion formation. A large
multicenter, prospective, randomized, double-blind
study by Brown et al [175] compared Adept (N = 203)
with lactated Ringer’s solution (N = 199), in women
undergoing laparoscopic gynecologic surgery for adhe-
siolysis. The study patients returned for a second laparo-
scopy within 4 to 8 weeks. Adept was significantly more
likely to reduce adhesions and improve fertility scores
than lactated Ringer’s solution.
A multicenter RCT compare intraperitoneal 4% ico-
dextrin (ID) solution with lactated Ringer’ss o l u t i o n
(LRS) on adhesion formation after Hartmann’sp r o c e -
dure [176]. The adhesiolysis surgery time during Hart-
man’s reversal was used as a marker of the severity of
adhesions. On completion of 17 eligible patients, an
interim analysis was performed. There were no compli-
cations following the use of 4% ID solution. The mean
(SD) total adhesiolysis times in patients treated with 4%
ID solution and LRS were 30.8 (18.0) min and 47.6
(45.7) min, respectively. The mean reduction of 16.8
min, although greater than expected, was not statistically
significant (P = 0.33) because of the large variance in
adhesiolysis times. However in interpreting the results
of this study, has to be highlighted that it was under-
powered to meet the study end-point.
The most recent Italian RCT [177] on use of icodex-
trin 4% solution for prevention of postoperative abdom-
inal adhesions after laparotomic operation for small
bowel obstruction caused by adherences, included 169
patients randomised to either Icodextrin 4% or control
and demonstrated a significant (p < 0.05) reduction of
ASBO recurrences in the study group after a mean fol-
low up period of 42 months, as well as a trend, although
not statistically significant, in decreasing the incidence
of recurrences needing surgery and the severity of
adhesions.
The ARIEL registry [178] (multicentre Adept Registry
for Clinical Evaluation) was established to gather clini-
cal experiences in the use of icodextrin 4% solution, an
approved adhesion-reduction agent, during routine
general surgery. General surgeons from five European
countries completed anonymised data collection forms
for patients undergoing laparotomy or laparoscopy.
Surgeons recorded patientd e m o g r a p h i c s ,u s eo f
icodextrin 4% solution and adverse events, and made
subjective assessments of ease of use and patient
acceptability with the agent. This registry showed that
the volumes of icodextrin 4% solution used as an irri-
gant and instillate were in line with recommendations
(1-l instillation and 100 ml every 30 min for irrigation).
Surgeons considered the agent to be easy to use and
acceptable to patients. The reported frequencies of
a d v e r s ee v e n t sw e r ei nl i n ew i t ht h o s ep u b l i s h e di nt h e
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safety profile of this agent.
Intergel solution (Lifecore Biomedical, Inc, Chaska,
MN), which contains .5% ferric hyaluronate, is another
solution used for adhesion prevention. In preliminary
studies it has been shown to reduce the number, sever-
ity, and extent of adhesions in peritoneal surgery [179].
However, the use of Intergel in abdominal surgery in
which the gastrointestinal tract was opened led to an
unacceptably high rate of postoperative complications
[180].
Miscellanous
An interesting experimental finding is the reduction of
both number and type of adhesions after postoperative
stimulation of gastrointestinal motility by a prokinetic
agent [181].
Finally merits mention that peritoneal infusion with
cold saline has shown to decrease the degree of post-
operative intra-abdominal adhesion formation in an ani-
mal model [182].
Audience and Panelists Remarks
PREVENTION:
“the cited metanalysis contains only one RCT. So
change LOE from 1a to 1b”
VAN GOOR
“the statement PATIENTS WHO HAD SURGERY
WITHIN 6 WEEKS, should be taken out from the
exclusion criteria for NOM”
PINNA AD, SUGABAKER
“the CT scan findings and the factors predictive of
surgery, derived from the paper WJS 2010 from the
group of Mayo Clinic - M. Sarr, should be defined
further clarifying their OR, from the more weak (lack of
feaces sign) to the strongest. Should also be highlighted
that the combination of the 4 factors has an higher OR
(16...) and therefore the combined presence has an
higher GoR”
M. VALENTINO
“t h ew e a ke v i d e n c eo ft h ev a l u eo ft h es m a l lb o w e l
faeces sign should be highlighted”
M. VALENTINO
“the citation of the paper studying the effect of high
oxygen on the conservative management of ASBO
should be included in the paper and this effect of high
oxygen should included in the guidelines”
http://www.ncbi.nlm.nih.gov/pubmed/18613394
VAN GOOR
“change the definition if ILEUS persist with the defini-
tion if ASBO persist, since ileus in english refers usually
to postoperative ileus”
P. SUGARBAKER
“I would be more conservative with patients with recur-
rent ASBO. The limit of 72 hours for the indications for
surgery should be delayed for the patients with recurrent
ASBO”
C. BENDINELLI AND PINNA AD
Conclusions
ASBO is a common disease. Non operative management
should be attempted in absence of signs of peritonitis or
strangulation. WSCM is safe and has a definite role in
diagnosis (for predicting the resolution or need for sur-
gery) and therapy (for reducing the operative rate and
shortening time to resolution of symptoms and hospital
stay). Open surgery remains the safest and most effec-
tive operative approach. Prevention with hyaluronic
acid-carboxycellulose membrane or icodextrin, has actu-
ally a capital relevance.
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